Financings In Brief
This article was originally published in The Gray Sheet
Executive SummaryIDEV raises $46 mil. for stent trial
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.